Pettiti Gianluca 4

What Happened Gianluca Pettiti, Executive Vice President of Thermo Fisher Scientific (TMO), received three equity awards recorded on Feb 25, 2026. The Form 4 shows acquisitions (code A) of 2,057 shares, 3,715 shares, and 16,270 shares (the last reported as a derivative), all reported at $0.00. These are grants/awards (not open‑market purchases or sales) and reflect compensation rather than a cash transaction.

Key Details

• Transaction date: 2026-02-25; Form 4 filed: 2026-02-27 (filed two days after the transaction).
• Reported entries: 2,057 shares @ $0.00; 3,715 shares @ $0.00; 16,270 shares (derivative) @ $0.00 — total 22,042 shares.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote F1: Describes a performance‑based restricted stock unit (RSU) award granted Feb 19, 2025; the Compensation Committee certified performance on Feb 25, 2026. One‑third vests on Feb 28, 2026 and 2027; the final third vests Feb 28, 2028 and may be adjusted up or down based on long‑term TSR performance vs. peers over 2025–2027.
• Footnote F2: Notes an option that vests in four equal annual installments beginning Feb 28, 2027.
• Timeliness: Filing appears timely (submitted two days after the reported transactions).

Context These entries are equity compensation awards (including performance‑based RSUs and an option with a multi‑year vesting schedule), meaning Pettiti has the right to receive shares upon vesting and/or satisfaction of performance conditions rather than having bought or sold stock in the open market. Such awards are routine for executives and are intended as long‑term incentive compensation; they do not by themselves indicate immediate buying or selling sentiment.